Amid strong growth across all verticals, Biocon, a key player in the biotechnology industry, announced a 71% increase in its consolidated net profit for the June quarter, coming in at Rs144 crore.
In the April through June quarter of the prior fiscal year, the firm reported a net profit of Rs84 crore. In the first quarter, total sales increased to Rs2,217 crore from Rs1,808 crore in the same quarter last year, according to a regulatory filing by Biocon.
Revenues increased, according to Kiran Mazumdar-Shaw, executive chairman of Biocon, as a consequence of the sector’s strong growth in both generics and biosimilars.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
